Research progress of nutritional and inflammatory markers in evaluating the prognosis of resectable pancreatic cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LU Shaobin ¹ , YE Cheng ² ,  ZHOU Wence ³

1. The First School of Clinical Medicine of Lanzhou University, Lanzhou 730000, P. R. China;
2. Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, P. R. China;
3. Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou 730000, P. R. China;

Corresponding author：

ZHOU Wence, Email: zhouwc129@163.com

Keywords：

resectable pancreatic cancer; nutrition; inflammatory marker; prognosis

DOI：

10.7507/1007-9424.202206007

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the application of nutritional and inflammatory markers in the prognosis assessment of resectable pancreatic cancer, and to provide new ideas for the prognosis assessment of patients with pancreatic cancer. Method The recent studies on nutritional and inflammatory markers for prognosis of resectable pancreatic cancer at home and abroad were reviewed. Results Radical pancreaticoduodenectomy was the preferred treatment for patients with resectable pancreatic cancer. Poor nutritional status and severe systemic inflammatory response were closely related to postoperative tumor recurrence and other poor prognosis. Nutritional and inflammatory markers played an important role in evaluating the prognosis of resectable pancreatic cancer. Conclusion Nutritional and inflammatory markers, as simple and economical prognostic indicators, have broad clinical application prospects in the prognostic assessment of resectable pancreatic cancer.

Citation： LU Shaobin, YE Cheng, ZHOU Wence. Research progress of nutritional and inflammatory markers in evaluating the prognosis of resectable pancreatic cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(12): 1660-1666. doi: 10.7507/1007-9424.202206007 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Kondo N, Murakami Y, Uemura K, et al. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Pancreatology, 2017, 17(1): 95-102.
3.	Bye A, Jordhøy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer, 2013, 21(1): 219-227.
4.	Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity, 2019, 51(1): 27-41.
5.	Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg, 2020, 271(4): 693-700.
6.	Capurso G, Pecorelli N, Burini A, et al. The impact of nutritional status on pancreatic cancer therapy. Expert Rev Anticancer Ther, 2022, 22(2): 155-167.
7.	韦荣泉, 兰梅卉, 陈英. 恶性肿瘤相关营养筛查和评估工具的研究进展. 癌症进展, 2021, 19(4): 325-328.
8.	Xu JY, Tian XD, Song JH, et al. Preoperative nutrition support may reduce the prevalence of postoperative pancreatic fistula after open pancreaticoduodenectomy in patients with high nutritional risk determined by NRS2002. Biomed Res Int, 2021, 2021: 6691966. doi: 10.1155/2021/6691966.
9.	Zhang Q, Li XR, Zhang X, et al. PG-SGA SF in nutrition assessment and survival prediction for elderly patients with cancer. BMC Geriatr, 2021, 21(1): 687. doi: 10.1186/s12877-021-02662-4.
10.	Qi Q, Song Q, Cheng Y, et al. Prognostic significance of preoperative prognostic nutritional index for overall survival and postoperative complications in esophageal cancer patients. Cancer Manag Res, 2021, 13: 8585-8597.
11.	Pointer DT Jr, Roife D, Powers BD, et al. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer, 2020, 20(1): 750. doi: 10.1186/s12885-020-07182-9.
12.	Wu L, Saxena S, Singh RK. Singh neutrophils in the tumor microenvironment. Adv Exp Med Biol, 2020, 1224: 1-20.
13.	Farhood B, Najafi M, Mortezaee K. Mortezaee CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol, 2019, 234(6): 8509-8521.
14.	Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124. doi: 10.1093/jnci/dju124.
15.	Sierzega M, Lenart M, Rutkowska M, et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol, 2017, 24(3): 808-815.
16.	Zhou Y, Wei Q, Fan J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8 252 patients. Clin Chim Acta, 2018, 479: 181-189.
17.	Chawla A, Huang TL, Ibrahim AM, et al. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB (Oxford), 2018, 20(5): 398-404.
18.	Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2011, 18(8): 2318-28.
19.	Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev, 2017, 36(2): 249-262.
20.	Chen C, Yang H, Cai D, et al. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res, 2021, 10(2): 866-877.
21.	Huang H, Wu K, Chen L, et al. Study on the Application of Systemic Inflammation Response Index and Platelet-Lymphocyte Ratio in Ovarian Malignant Tumors. Int J Gen Med, 2021, 14: 10015-10022.
22.	Huang H, Sun J, Jiang Z, et al. Risk factors and prognostic index model for pancreatic cancer. Gland Surg, 2022, 11(1): 186-195.
23.	Asari S, Matsumoto I, Toyama H, et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today, 2016, 46(5): 583-92.
24.	Watanabe J, Otani S, Sakamoto T, et al. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Surg Today, 2016, 46(11): 1258-67.
25.	Song W, Tian C, Wang K, et al. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis. PLoS One, 2017, 12(6): e0178762. doi: 10.1371/journal.pone.0178762.
26.	Pan Y, Yu Y, Wang X, et al. Tumor-associated macrophages in tumor immunity. Front Immunol, 2020, 11: 583084. doi: 10.3389/fimmu.2020.583084.
27.	Goto W, Kashiwagi S, Asano Y, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer, 2018, 18(1): 1137. doi: 10.1186/s12885-018-5051-9.
28.	Kubota K, Shimizu A, Notake T, et al. Preoperative peripheral blood lymphocyte-to-monocyte ratio predicts long-term outcome for patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2022, 29(2): 1437-1448.
29.	Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis. Clin Chim Acta, 2018, 481: 142-146.
30.	Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer, 2016, 122(14): 2158-67.
31.	He Q, Li L, Ren Q. The prognostic value of preoperative systemic inflammatory response index (siri) in patients with high-grade glioma and the establishment of a Nomogram. Front Oncol, 2021, 11: 671811. doi: 10.3389/fonc.2021.671811.
32.	Li S, Xu H, Wang W, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res, 2019, 11: 3327-3337.
33.	Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: A retrospective multicenter cohort study. Ann Surg, 2019, 270(1): 139-146.
34.	Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the systemic immune-inflammation index (sii) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol, 2020, 27(3): 898-906.
35.	Liu T, Zhang Q, Song C, et al. C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study. Int J Cancer, 2022, 151(2): 297-307.
36.	van Atteveld VA, Van Ancum JM, Reijnierse EM, et al. Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study. BMC Geriatr, 2019, 19(1): 233. doi: 10.1186/s12877-019-1253-5.
37.	Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clinical Medicine, 2009, 9(1): 30-33.
38.	Fan Z, Fan K, Gong Y, et al. The CRP/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. Cancer Manag Res, 2019, 11: 8781-8788.
39.	Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol, 2017, 24(2): 561-568.
40.	罗宝洋, 杨勇, 段云飞, 等. 术前C反应蛋白和清蛋白比值对可切除胰腺癌患者预后的影响. 中华外科杂志, 2018, 56(9): 712-717.
41.	张博林, 徐新建. C反应蛋白与白蛋白比值预测胰腺癌患者预后价值的meta分析. 中国普外基础与临床杂志, 2022, 29(3): 345-352.
42.	McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev, 2013, 39(5): 534-40.
43.	Hong S, Hwang DW, Lee JH, et al. Usefulness of inflammation-based prognostic scores in patients with surgically treated pancreatic ductal adenocarcinoma. J Clin Med, 2021, 10(24): 5784. doi: 10.3390/jcm10245784.
44.	Hacker UT, Hasenclever D, Baber R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol, 2022, 33(7): 685-692.
45.	Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg, 1980, Jan,139: 160-167.
46.	Zhang H, Shang X, Ren P, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol, 2019, 234(2): 1794-1802.
47.	Abe T, Nakata K, Kibe S, et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2018, 25(13): 3996-4003.
48.	Liu J, Jiang S, Yang X, Li X, et al. The significant value of preoperative prognostic nutritional index for survival in pancreatic cancers: a meta-analysis. Pancreas, 2018, 47(7): 793-799.
49.	Li S, Tian G, Chen Z, et al. Prognostic role of the prognostic nutritional index in pancreatic cancer: a meta-analysis. Nutr Cancer, 2019, 71(2): 207-213.
50.	Nakagomi A, Kohashi K, Morisawa T, et al. Nutritional status is associated with inflammation and predicts a poor outcome in patients with chronic heart failure. J Atherosc Thromb, 2016, 23(6): 713-727.
51.	Wang A, Sun B, Wang M, et al. Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study. PeerJ, 2020, 8: e8811. doi: 10.7717/peerj.8811.
52.	Kheirouri S, Alizadeh M. Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: a systematic review. Adv Nutr, 2021, 12(1): 234-250.
53.	Yang C, Wei C, Wang S, et al. Combined features based on preoperative controlling nutritional status score and circulating tumour cell status predict prognosis for colorectal cancer patients treated with curative resection. Int J Biol Sci, 2019, 15(6): 1325-1335.
54.	Terasaki F, Sugiura T, Okamura Y, et al. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Updates Surg, 2021, 73(1): 251-259.
55.	Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non‐small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 2013, 13: 158. doi: 10.1186/1471-2407-13-158.
56.	Barth DA, Brenner C, Riedl JM, et al. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Cancer Med, 2020, 9(15): 5473-5479.
57.	Topkan E, Mertsoylu H, Ozdemir Y, et al. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy. Cancer Manag Res, 2019, 11: 8807-8815.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Kondo N, Murakami Y, Uemura K, et al. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. Pancreatology, 2017, 17(1): 95-102.
3. Bye A, Jordhøy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer, 2013, 21(1): 219-227.
4. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity, 2019, 51(1): 27-41.
5. Okadome K, Baba Y, Yagi T, et al. Prognostic nutritional index, tumor-infiltrating lymphocytes, and prognosis in patients with esophageal cancer. Ann Surg, 2020, 271(4): 693-700.
6. Capurso G, Pecorelli N, Burini A, et al. The impact of nutritional status on pancreatic cancer therapy. Expert Rev Anticancer Ther, 2022, 22(2): 155-167.
7. 韦荣泉, 兰梅卉, 陈英. 恶性肿瘤相关营养筛查和评估工具的研究进展. 癌症进展, 2021, 19(4): 325-328.
8. Xu JY, Tian XD, Song JH, et al. Preoperative nutrition support may reduce the prevalence of postoperative pancreatic fistula after open pancreaticoduodenectomy in patients with high nutritional risk determined by NRS2002. Biomed Res Int, 2021, 2021: 6691966. doi: 10.1155/2021/6691966.
9. Zhang Q, Li XR, Zhang X, et al. PG-SGA SF in nutrition assessment and survival prediction for elderly patients with cancer. BMC Geriatr, 2021, 21(1): 687. doi: 10.1186/s12877-021-02662-4.
10. Qi Q, Song Q, Cheng Y, et al. Prognostic significance of preoperative prognostic nutritional index for overall survival and postoperative complications in esophageal cancer patients. Cancer Manag Res, 2021, 13: 8585-8597.
11. Pointer DT Jr, Roife D, Powers BD, et al. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. BMC Cancer, 2020, 20(1): 750. doi: 10.1186/s12885-020-07182-9.
12. Wu L, Saxena S, Singh RK. Singh neutrophils in the tumor microenvironment. Adv Exp Med Biol, 2020, 1224: 1-20.
13. Farhood B, Najafi M, Mortezaee K. Mortezaee CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol, 2019, 234(6): 8509-8521.
14. Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst, 2014, 106(6): dju124. doi: 10.1093/jnci/dju124.
15. Sierzega M, Lenart M, Rutkowska M, et al. Preoperative neutrophil-lymphocyte and lymphocyte-monocyte ratios reflect immune cell population rearrangement in resectable pancreatic cancer. Ann Surg Oncol, 2017, 24(3): 808-815.
16. Zhou Y, Wei Q, Fan J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8 252 patients. Clin Chim Acta, 2018, 479: 181-189.
17. Chawla A, Huang TL, Ibrahim AM, et al. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. HPB (Oxford), 2018, 20(5): 398-404.
18. Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2011, 18(8): 2318-28.
19. Wojtukiewicz MZ, Sierko E, Hempel D, et al. Platelets and cancer angiogenesis nexus. Cancer Metastasis Rev, 2017, 36(2): 249-262.
20. Chen C, Yang H, Cai D, et al. Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer. Transl Lung Cancer Res, 2021, 10(2): 866-877.
21. Huang H, Wu K, Chen L, et al. Study on the Application of Systemic Inflammation Response Index and Platelet-Lymphocyte Ratio in Ovarian Malignant Tumors. Int J Gen Med, 2021, 14: 10015-10022.
22. Huang H, Sun J, Jiang Z, et al. Risk factors and prognostic index model for pancreatic cancer. Gland Surg, 2022, 11(1): 186-195.
23. Asari S, Matsumoto I, Toyama H, et al. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios. Surg Today, 2016, 46(5): 583-92.
24. Watanabe J, Otani S, Sakamoto T, et al. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Surg Today, 2016, 46(11): 1258-67.
25. Song W, Tian C, Wang K, et al. Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis. PLoS One, 2017, 12(6): e0178762. doi: 10.1371/journal.pone.0178762.
26. Pan Y, Yu Y, Wang X, et al. Tumor-associated macrophages in tumor immunity. Front Immunol, 2020, 11: 583084. doi: 10.3389/fimmu.2020.583084.
27. Goto W, Kashiwagi S, Asano Y, et al. Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer. BMC Cancer, 2018, 18(1): 1137. doi: 10.1186/s12885-018-5051-9.
28. Kubota K, Shimizu A, Notake T, et al. Preoperative peripheral blood lymphocyte-to-monocyte ratio predicts long-term outcome for patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2022, 29(2): 1437-1448.
29. Hu RJ, Ma JY, Hu G. Lymphocyte-to-monocyte ratio in pancreatic cancer: Prognostic significance and meta-analysis. Clin Chim Acta, 2018, 481: 142-146.
30. Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer, 2016, 122(14): 2158-67.
31. He Q, Li L, Ren Q. The prognostic value of preoperative systemic inflammatory response index (siri) in patients with high-grade glioma and the establishment of a Nomogram. Front Oncol, 2021, 11: 671811. doi: 10.3389/fonc.2021.671811.
32. Li S, Xu H, Wang W, et al. The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res, 2019, 11: 3327-3337.
33. Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: A retrospective multicenter cohort study. Ann Surg, 2019, 270(1): 139-146.
34. Murthy P, Zenati MS, Al Abbas AI, et al. Prognostic value of the systemic immune-inflammation index (sii) after neoadjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol, 2020, 27(3): 898-906.
35. Liu T, Zhang Q, Song C, et al. C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study. Int J Cancer, 2022, 151(2): 297-307.
36. van Atteveld VA, Van Ancum JM, Reijnierse EM, et al. Erythrocyte sedimentation rate and albumin as markers of inflammation are associated with measures of sarcopenia: a cross-sectional study. BMC Geriatr, 2019, 19(1): 233. doi: 10.1186/s12877-019-1253-5.
37. Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clinical Medicine, 2009, 9(1): 30-33.
38. Fan Z, Fan K, Gong Y, et al. The CRP/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. Cancer Manag Res, 2019, 11: 8781-8788.
39. Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol, 2017, 24(2): 561-568.
40. 罗宝洋, 杨勇, 段云飞, 等. 术前C反应蛋白和清蛋白比值对可切除胰腺癌患者预后的影响. 中华外科杂志, 2018, 56(9): 712-717.
41. 张博林, 徐新建. C反应蛋白与白蛋白比值预测胰腺癌患者预后价值的meta分析. 中国普外基础与临床杂志, 2022, 29(3): 345-352.
42. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev, 2013, 39(5): 534-40.
43. Hong S, Hwang DW, Lee JH, et al. Usefulness of inflammation-based prognostic scores in patients with surgically treated pancreatic ductal adenocarcinoma. J Clin Med, 2021, 10(24): 5784. doi: 10.3390/jcm10245784.
44. Hacker UT, Hasenclever D, Baber R, et al. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. Ann Oncol, 2022, 33(7): 685-692.
45. Buzby GP, Mullen JL, Matthews DC, et al. Prognostic nutritional index in gastrointestinal surgery. Am J Surg, 1980, Jan,139: 160-167.
46. Zhang H, Shang X, Ren P, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol, 2019, 234(2): 1794-1802.
47. Abe T, Nakata K, Kibe S, et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2018, 25(13): 3996-4003.
48. Liu J, Jiang S, Yang X, Li X, et al. The significant value of preoperative prognostic nutritional index for survival in pancreatic cancers: a meta-analysis. Pancreas, 2018, 47(7): 793-799.
49. Li S, Tian G, Chen Z, et al. Prognostic role of the prognostic nutritional index in pancreatic cancer: a meta-analysis. Nutr Cancer, 2019, 71(2): 207-213.
50. Nakagomi A, Kohashi K, Morisawa T, et al. Nutritional status is associated with inflammation and predicts a poor outcome in patients with chronic heart failure. J Atherosc Thromb, 2016, 23(6): 713-727.
51. Wang A, Sun B, Wang M, et al. Predictive value of CONUT score combined with serum CA199 levels in postoperative survival of patients with pancreatic ductal adenocarcinoma: a retrospective study. PeerJ, 2020, 8: e8811. doi: 10.7717/peerj.8811.
52. Kheirouri S, Alizadeh M. Prognostic potential of the preoperative controlling nutritional status (CONUT) score in predicting survival of patients with cancer: a systematic review. Adv Nutr, 2021, 12(1): 234-250.
53. Yang C, Wei C, Wang S, et al. Combined features based on preoperative controlling nutritional status score and circulating tumour cell status predict prognosis for colorectal cancer patients treated with curative resection. Int J Biol Sci, 2019, 15(6): 1325-1335.
54. Terasaki F, Sugiura T, Okamura Y, et al. The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma. Updates Surg, 2021, 73(1): 251-259.
55. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non‐small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 2013, 13: 158. doi: 10.1186/1471-2407-13-158.
56. Barth DA, Brenner C, Riedl JM, et al. External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Cancer Med, 2020, 9(15): 5473-5479.
57. Topkan E, Mertsoylu H, Ozdemir Y, et al. Prognostic usefulness of advanced lung cancer inflammation index in locally-advanced pancreatic carcinoma patients treated with radical chemoradiotherapy. Cancer Manag Res, 2019, 11: 8807-8815.

Previous Article
Research status of patient-reported outcome in esophageal carcinoma surgery
Next Article
Research status of patient-reported outcome in esophageal carcinoma surgery

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of nutritional and inflammatory markers in evaluating the prognosis of resectable pancreatic cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content